Nisotirostide clinical trials
Also written LY3457263.
How each study uses nisotirostide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nisotirostide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY3457263
- 4
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nisotirostide.
- May 2027A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatidePhase 2 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses nisotirostide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideRecruitingPhase 2Eli Lilly and CompanyNCT06897475Written as LY3457263
- A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT05377333Written as LY3457263
- A Study of LY3457263 in Obese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05582096Written as LY3457263
- A Study of LY3457263 in Healthy Participants and Participants With Type 2 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT04641312Written as LY3457263
Codes
What other systems call nisotirostide · ClinicalTrials.gg INT014717
- UNII (FDA) 3R5UFO57X5NISOTIROSTIDEOne source FDA
- NCI Thesaurus C199078NisotirostideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3R5UFO57X5 | NISOTIROSTIDE | One source FDA |
| NCI Thesaurus | C199078 | Nisotirostide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.